GlassScriptPhysician profile
John C Canzano
NPI 1134232648
$3,689.73
in general payments reported to CMS, 2019-2025
28 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $283 · 2021: $351 · 2022: $570 · 2023: $587 · 2024: $643 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $864.29 | 2019-2025 | Ngenuity, Tryptyr, Clareon |
| Genentech USA, INC. | $644.61 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $355.73 | 2019-2023 | |
| Abbvie INC. | $344.73 | 2023-2025 | Lumigan, Alphagan P |
| Astellas Pharma US INC | $167.19 | 2023-2024 | Izervay |
| Omeros Corporation | $131.38 | 2019-2021 | |
| Allergan, INC. | $118.68 | 2019-2021 | |
| Rxsight INC | $108.94 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Eyevance Pharmaceuticals LLC | $86.76 | 2021 | |
| Biotissue Holdings INC. | $78.30 | 2025 | |
| Horizon Therapeutics Plc | $77.67 | 2023 | Tepezza |
| Harrow Eye, LLC | $75.26 | 2024 | Iheezo |
| Beaver-Visitec International, INC. | $73.65 | 2019-2023 | |
| Dompe US, INC. | $72.52 | 2024-2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $64.59 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $64.34 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $52.43 | 2023-2025 | Omidria, Rayone Emv, Rayone Aspheric |
| Tarsus Pharmaceuticals, INC. | $48.27 | 2025 | Xdemvy |
| New World Medical,INC. | $45.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $44.78 | 2020-2023 | Eylea |
| Oyster Point Pharma, INC. | $31.30 | 2023 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $29.40 | 2025 | Syfovre |
| Amgen INC. | $25.69 | 2024 | Tepezza |
| Sight Sciences, INC. | $23.92 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $16.70 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.65 | 2022 | |
| Iridex Corporation | $10.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Canzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.